Analyst Price Target is $60.25
▲ +65.11% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $60.25, with a high forecast of $74.00 and a low forecast of $52.00. The average price target represents a 65.11% upside from the last price of $36.49.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Adaptive Biotechnologies. This Buy consensus rating has held steady for over two years.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.